Tate & Lyle (GB:TATE)
LSE:TATE
Top Page
Tate & Lyle
(LSE:TATE)
Select Model
Select Model
Rating:65Neutral
Price Target:
356.00 p
▼(-3.00% Downside)
Action:ReiteratedDate:12/07/25
Tate & Lyle's overall stock score reflects stable financial performance and positive corporate events, such as insider share purchases. However, technical indicators and valuation suggest caution, with high P/E ratios and neutral momentum. Earnings call insights highlight current market challenges, balancing the positive aspects.
Positive Factors
Diverse specialty ingredients portfolio
A broad mix of specialty sweeteners, starch-based texturants, fibers and proteins gives Tate & Lyle durable product diversification. Its B2B formulation support deepens customer relationships, increases inclusion rates and creates recurring revenue streams that support stable demand over multiple quarters.
Negative Factors
Tariff exposure
Persistent tariff and trade barriers affecting a few percent of revenue can structurally raise input and logistics costs or force margin erosion via price concessions. Geographic flow disruptions (eg, Brazil to North America) complicate supply planning and can reduce competitiveness across quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Diverse specialty ingredients portfolio
A broad mix of specialty sweeteners, starch-based texturants, fibers and proteins gives Tate & Lyle durable product diversification. Its B2B formulation support deepens customer relationships, increases inclusion rates and creates recurring revenue streams that support stable demand over multiple quarters.
Read all positive factors
Tate & Lyle (TATE) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£1.58B
Dividend Yield5.27%
Average Volume (3M)2.61M
Price to Earnings (P/E)8.9
Beta (1Y)0.78
Revenue Growth26.84%
EPS Growth-81.73%
CountryUK
Employees3,318
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.21
Shares Outstanding445,446,780
10 Day Avg. Volume2,809,626
30 Day Avg. Volume2,611,880
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)4.01
Price to Sales (P/S)3.67
P/FCF Ratio148.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£297.98Price Target Upside-18.81% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.41
Revenue Forecast (FY)£2.02B
Tate & Lyle Business Overview & Revenue Model
Company Description
Tate & Lyle PLC, together with its subsidiaries, provides ingredients and solutions to the food, beverage, and other industries in the United States, the United Kingdom, other European countries, and internationally. It operates through three segm...
How the Company Makes Money
Tate & Lyle makes money by selling specialty ingredient products and solutions to business customers (primarily food and beverage manufacturers) and recognizing revenue when control of those goods transfers under supply agreements and purchase ord...
Tate & Lyle Earnings Call Summary
Earnings Call Date:Nov 06, 2025
(Q2-2026)
| % Change Since: |
Next Earnings Date:May 21, 2026
Earnings Call Sentiment Neutral
The earnings call reflects progress with the CP Kelco merger and strong sucralose demand, but it is overshadowed by a revenue and EBITDA decline, tough market conditions, and tariff impacts. The company is taking steps to accelerate growth, but current challenges are significant.Positive Updates
CP Kelco Combination Success
The combination with CP Kelco has led to early cross-selling successes, doubling the value of the pipeline in the last two months. This demonstrates the strategic logic of the merger and reinforces growth potential.
Negative Updates
Revenue and EBITDA Decline
First half Group revenue is expected to be 3% to 4% lower in constant currency compared to pro forma comparatives, with EBITDA expected to be high single-digit percent lower.
Read all updates
Q2-2026 Updates
Positive
Negative
CP Kelco Combination Success
The combination with CP Kelco has led to early cross-selling successes, doubling the value of the pipeline in the last two months. This demonstrates the strategic logic of the merger and reinforces growth potential.
Read all positive updates
Company Guidance
During the call, Nick Hampton, CEO of Tate & Lyle, provided guidance indicating that for the first half of fiscal year 2026, in constant currency, group revenue is expected to be 3% to 4% lower compared to pro forma comparatives, while EBITDA is anticipated to decline by high single-digit percent due to top-line softness and planned cost synergies being weighted into the second half. The Americas are expected to see slightly lower revenue, Europe, Middle East, and Africa a mid-single-digit decline, and Asia Pacific's revenue should remain stable despite tariff impacts. For the full year ending March 31, 2026, revenue and EBITDA are expected to decline by low single-digit percent, driven by challenging market conditions. The company remains focused on leveraging the strategic benefits of its CP Kelco combination, which has already seen the cross-selling pipeline double in value over the past two months, and plans to accelerate growth through customer segmentation, innovation, and productivity optimization.Tate & Lyle Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.99B | 1.74B | 1.65B | 1.75B | 1.38B | 1.21B |
| Gross Profit | -69.00M | 706.00M | 851.00M | 733.00M | 514.00M | 481.00M |
| EBITDA | 254.00M | 254.00M | 345.00M | 279.00M | 168.00M | 292.00M |
| Net Income | 34.00M | 143.00M | 188.00M | 190.00M | 236.00M | 253.00M |
Balance Sheet | ||||||
| Total Assets | 3.60B | 3.73B | 2.28B | 2.51B | 3.25B | 2.97B |
| Cash, Cash Equivalents and Short-Term Investments | 325.00M | 334.00M | 437.00M | 475.00M | 112.00M | 371.00M |
| Total Debt | 1.29B | 1.31B | 590.00M | 713.00M | 679.00M | 786.00M |
| Total Liabilities | 2.05B | 2.14B | 1.04B | 1.32B | 1.63B | 1.51B |
| Stockholders Equity | 1.55B | 1.59B | 1.24B | 1.19B | 1.62B | 1.45B |
Cash Flow | ||||||
| Free Cash Flow | 71.00M | 43.00M | 98.00M | -12.00M | -45.00M | 217.00M |
| Operating Cash Flow | 188.00M | 164.00M | 208.00M | 66.00M | 103.00M | 369.00M |
| Investing Cash Flow | -931.00M | -630.00M | -20.00M | 835.00M | -113.00M | -205.00M |
| Financing Cash Flow | 452.00M | 367.00M | -215.00M | -598.00M | -247.00M | -29.00M |
Tate & Lyle Technical Analysis
Negative
367.00
Price Trends
372.00
Negative
372.35
Negative
425.05
Negative
Market Momentum
-10.16
Negative
45.00
Neutral
59.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TATE, the sentiment is Negative. The current price of 367 is above the 20-day moving average (MA) of 348.57, below the 50-day MA of 372.00, and below the 200-day MA of 425.05, indicating a neutral trend. The MACD of -10.16 indicates Negative momentum. The RSI at 45.00 is Neutral, neither overbought nor oversold. The STOCH value of 59.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:TATE.
Tate & Lyle Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £72.11M | 6.77 | 13.66% | 2.42% | 34.26% | 71.40% | |
69 Neutral | £13.01B | 15.47 | 9.22% | 2.98% | -3.06% | -26.93% | |
65 Neutral | £1.58B | 8.87 | 2.17% | 5.27% | 26.84% | -81.73% | |
64 Neutral | £67.07M | 5.65 | 28.53% | 3.14% | ― | ― | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
53 Neutral | £27.51M | -15.56 | 520.55% | ― | 147.18% | 3.11% |
* Consumer Defensive Sector Average
GB:TATE
Tate & Lyle
358.80
-142.12
-28.37%
GB:ABF
Associated British Foods
1,849.50
-20.51
-1.10%
GB:ANP
Anpario
430.00
52.34
13.86%
GB:FVA
Fevara plc
129.50
5.64
4.55%
GB:SALT
MicroSalt plc
49.00
-8.50
-14.78%
Tate & Lyle Corporate Events
Business Operations and StrategyFinancial Disclosures
Tate & Lyle Holds Outlook as CP Kelco Synergies Offset Muted Demand
Neutral
Feb 26, 2026
Tate Lyle reported third-quarter trading in line with expectations, with group revenue up 15% on a reported basis for the three months to 31 December 2025, driven largely by its combination with CP Kelco. On a pro forma basis, revenue declined 2%...
Business Operations and StrategyExecutive/Board Changes
Tate & Lyle Reshapes Board as Major Shareholder Huber Appoints New Non-Executive Director
Positive
Jan 21, 2026
Tate Lyle has announced that Glenn M. Fish, originally appointed to its board in 2024 as a nominee of major shareholder J.M. Huber Corporation, has resigned as a director following his promotion to President and CEO of Huber. In line with Huber&#...
Regulatory Filings and Compliance
Tate & Lyle Director Increases Stake With ADR Purchase
Positive
Jan 7, 2026
Tate Lyle has disclosed that non-executive director Claudia Vaz de Lestapis and a person closely associated with her, Alexandre Samuel Pierre Marie de Lestapis, purchased 5,000 American Depositary Receipts in the company on 6 January 2026 at a pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.